Full-Time
Posted on 6/26/2025
Biopharma developing eye-care therapies
$131.2k - $183.8k/yr
Lexington, KY, USA + 3 more
More locations: Cleveland, OH, USA | Columbus, OH, USA | Cincinnati, OH, USA
In Person
Territory includes OH, Detroit Metro area, KY, and Western PA; field-based with 60-80% travel; candidates must reside in assigned territory, with preference for those within 45 minutes of a major airport.
| , |
Tarsus Pharmaceuticals develops treatments for eye care and infectious diseases. Its FDA-approved product, XDEMVY (lotilaner ophthalmic solution 0.25%), treats Demodex Blepharitis by killing Demodex mites on the eyelids. The company also has a pipeline targeting conditions like Lyme Disease Prevention, Meibomian Gland Disease, and Rosacea, and it earns revenue from selling approved products and collaborating with partners. Its goal is to address unmet medical needs by developing, commercializing, and expanding collaborations to reach more patients.
Company Size
201-500
Company Stage
IPO
Headquarters
Irvine, California
Founded
2017
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Paid Vacation
Hybrid Work Options
Professional Development Budget
Tarsus Pharmaceuticals has dosed the first participant in its Phase 2 Calliope trial of TP-05, an investigational oral therapy aimed at preventing Lyme disease in approximately 700 at-risk adults across endemic US regions. The programme targets a significant unmet need as a potential first-in-class, non-vaccine prophylactic for Lyme disease, where no FDA-approved preventive drugs currently exist. Whilst the trial marks progress, near-term investment focus remains on XDEMVY adoption and margins. The company recently received a $15 million milestone payment tied to TP-03 approval in China, highlighting monetisation of its lotilaner platform beyond the US. Analyst projections for Tarsus vary widely, with some forecasting $847 million revenue and $237 million earnings by 2028, whilst more cautious estimates suggest $988 million revenue and $188 million earnings by 2029.
Dianne Whitfield, Chief Human Resources Officer at Tarsus Pharmaceuticals, sold 12,274 shares of common stock worth approximately $839,000 between 17 and 19 March 2026. The sale represented 25.95% of her direct holdings, reducing her position from 47,302 to 35,028 shares. The transaction was a mandatory "sell to cover" arrangement tied to RSU vesting for tax withholding purposes, rather than a discretionary sale. Shares sold at a weighted average price of $68.36. Tarsus Pharmaceuticals generated $451.4 million in net product sales in 2025, more than doubling from the prior year, driven by adoption of its lead product XDEMVY. The company narrowed its net loss to $66.4 million and ended 2025 with over $417 million in cash and marketable securities.
Tarsus Pharmaceuticals reported $450 million in full-year net sales for 2025, with its XDEMVY treatment achieving product-line profitability. The company has expanded its addressable market from nine million to 25 million Americans with Demodex blepharitis as screening becomes routine amongst eye care professionals. The firm projected 2026 net product sales between $670 million and $700 million, representing approximately 50% annual growth at the midpoint. Direct-to-consumer awareness reached 25% amongst surveyed patients, significantly increasing treatment requests. Tarsus plans to expand its sales force by 15 to 20 key account leaders and will initiate a Phase II trial for TP-05 in Lyme disease prevention in Q2 2026. The company has also launched the first Phase II trial for TP-04 in Ocular Rosacea, a category with no currently approved FDA treatments.
IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the pricing of...
Mutual of America Capital Management LLC invests $4.29 million in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS).